Johnson & Johnson (JNJ) to Release Quarterly Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ) will be issuing its quarterly earnings data before the market opens on Tuesday, April 16th. Analysts expect the company to announce earnings of $2.64 per share for the quarter. Johnson & Johnson has set its FY24 guidance at $10.55-10.75 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.35 EPS. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Trading Down 0.5 %

JNJ stock opened at $151.66 on Tuesday. The company has a market cap of $365.47 billion, a price-to-earnings ratio of 10.98, a PEG ratio of 2.56 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $157.92 and a 200-day simple moving average of $156.23. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97.

Insider Buying and Selling at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. FIDELIS iM LLC lifted its holdings in shares of Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after purchasing an additional 64 shares during the last quarter. Websterrogers Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.4% during the fourth quarter. Websterrogers Financial Advisors LLC now owns 2,875 shares of the company’s stock valued at $451,000 after purchasing an additional 68 shares during the last quarter. Tatro Capital LLC lifted its holdings in shares of Johnson & Johnson by 2.3% during the first quarter. Tatro Capital LLC now owns 3,059 shares of the company’s stock valued at $542,000 after purchasing an additional 69 shares during the last quarter. Palisades Hudson Asset Management L.P. lifted its holdings in shares of Johnson & Johnson by 5.0% during the second quarter. Palisades Hudson Asset Management L.P. now owns 1,721 shares of the company’s stock valued at $284,000 after purchasing an additional 82 shares during the last quarter. Finally, Tradewinds LLC. raised its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Tradewinds LLC. now owns 14,866 shares of the company’s stock worth $2,461,000 after acquiring an additional 90 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on JNJ shares. Raymond James increased their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $177.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.